在严重的COVID-19疾病中使用Interleukin 6对手:心血管和呼吸系统的结果
1Department of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al Hofuf, Saudi Arabia.
干白素6 (IL-6) 抑制剂通过调节免疫反应,在治疗严重的COVID-19方面表现有前途. 虽然结果各不相同,但有一种共识支持在重症患者中使用它们来对抗细胞因子风暴并改善结果.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 关键护理医学 关键护理医学
背景情况:
- 严重的COVID-19与细胞因子释放综合征 (CRS) 有关,其特征是炎症性细胞因子升高.
- 主体免疫反应虽然具有保护性,但在严重的情况下可能导致显著的组织损伤,败血症和器官衰竭.
研究的目的:
- 审查互白素6 (IL-6) 在COVID-19病变发生过程中的作用.
- 在临床试验中评估IL-6抑制剂在治疗COVID-19的疗效.
主要方法:
- 对COVID-19中IL-6抑制剂的现有文献和临床试验数据的审查.
- 对评估IL-6抑制剂作为严重COVID-19患者免疫调节剂的研究的分析.
主要成果:
- 在COVID-19中对IL-6抑制剂的临床试验产生了不同的结果.
- 一个普遍的共识支持IL-6抑制剂在重病COVID-19患者的使用,无论与德克萨米他一起使用时的具体结果如何.
结论:
- IL-6抑制剂代表了一种潜在的策略,用于调节严重COVID-19的炎症级联.
- 尽管有一些相互矛盾的数据,但IL-6抑制剂被认为是有利于管理患有细胞因子风暴的重症COVID-19患者.
更多相关视频
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Heart Failure Drugs: Inotropic Agents
